LTX-315
Intratumoral oncolytic peptide in clinical development — not approved.
What it's for
LTX-315 is an still being studied cationic peptide designed to kill tumor cells in a way that may stimulate anti-tumor immune responses.
What it does for the body
It has been studied as an intratumoral therapy aiming to induce local tumor cell death and immune activation. It is not an approved cancer drug. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
It disrupts mitochondrial and plasma membranes of cancer cells, promoting immunogenic cell death signals that can recruit immune effector cells. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: LTX-315 is still being studied in people. Watch for peer-reviewed trial readouts and regulator decisions — not just social-media summaries.
Studied for (literature interest)
- Skin research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: LTX-315 — FDA.gov search
- ClinicalTrials.gov search: LTX-315 — U.S. clinical trials registry
- Drugs@FDA search: LTX-315 — FDA drug database (if approved)
- PubMed search: LTX-315 — NCBI PubMed
- PubMed Central search: LTX-315 — NCBI PMC